Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Change in Receivables (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Change in Receivables for 6 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 44.64% year-over-year to $9.5 million, compared with a TTM value of $2.1 million through Dec 2025, down 63.25%, and an annual FY2025 reading of $2.1 million, down 63.25% over the prior year.
  • Change in Receivables was $9.5 million for Q4 2025 at Treace Medical Concepts, up from $2.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $17.2 million in Q4 2024 and bottomed at -$9.3 million in Q1 2025.
  • Average Change in Receivables over 5 years is $1.6 million, with a median of -$133000.0 recorded in 2022.
  • The sharpest move saw Change in Receivables plummeted 369.82% in 2021, then surged 343.49% in 2023.
  • Year by year, Change in Receivables stood at $7.0 million in 2021, then surged by 59.14% to $11.1 million in 2022, then grew by 20.95% to $13.4 million in 2023, then grew by 28.09% to $17.2 million in 2024, then tumbled by 44.64% to $9.5 million in 2025.
  • Business Quant data shows Change in Receivables for TMCI at $9.5 million in Q4 2025, $2.6 million in Q3 2025, and -$696000.0 in Q2 2025.